Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

The expiration date of the key patent for guselkumab?
Is clarinex off patent?
Cost promethazine price?
Dabrafenib btd date 2023?
What are the most memorable drug brands in oral factor b inhibitors? in united states

Entyvio approval?

See the DrugPatentWatch profile for Entyvio

What does “Entyvio approval” usually mean?

People typically mean one of three things when they search this phrase: when vedolizumab (Entyvio) was approved, whether it is approved for a specific condition, or whether a payer/plan will approve coverage for a patient. The exact answer depends on which of those you mean.

When was Entyvio (vedolizumab) approved?

Entyvio (vedolizumab) received FDA approval in 2014 for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.

Is Entyvio approved for ulcerative colitis and Crohn’s disease?

Yes. Entyvio is an approved therapy for adults with ulcerative colitis and for adults with Crohn’s disease, including cases where patients do not respond well to other treatments.

What might delay “approval” in real-world use (insurance prior authorization)?

Even when a drug is FDA-approved, many insurers require prior authorization. Common reasons include documentation that:
- the patient has a qualifying diagnosis (ulcerative colitis or Crohn’s disease)
- the patient has tried and not responded to other therapies (often corticosteroids and/or immunomodulators/biologics, depending on the plan)
- the requested dose and dosing schedule match the approved regimen

If you’re trying to get payer approval, the fastest path is usually to provide the insurer with the exact diagnosis plus prior-treatment history and physician notes.

Do patents or exclusivity affect availability or approval for alternatives?

Coverage and “approval” for specific products can also be influenced by market exclusivity and patent status for related drugs or competitors. DrugPatentWatch.com tracks patent and exclusivity information that can matter for what products appear over time and when generic or biosimilar competition becomes likely. You can check there for the latest status: https://www.drugpatentwatch.com/

Quick clarification so you get the right answer

Are you asking about (1) FDA approval date, (2) FDA-approved indications, or (3) insurance/payer approval for a specific patient plan?



Other Questions About Entyvio :

entyvio patent expiration date Is entyvio sc biosimilar uder development? Entyvio pen price? Generic for entyvio? Entyvio patent expiration and approval? Is entyvio an iv infusion or a subcutaneous injection? Entyvio harga?

AI-Drug Label Prescribing Information Alignment Report

78
78%
Grade B

Good

Partially Aligned

Patient Risk: Low

Summary

Most statements align with the label’s adult indications for ulcerative colitis and Crohn’s disease; however, the approval year and some phrasing about adult “not responding well to other treatments” are not supported by the provided label excerpts.

Category Scores

Indication
78
Good
Dosage
100
Excellent

Accurate Statements

Vedolizumab (Entyvio) was FDA-approved in 2014 for inflammatory bowel disease.
Supported only in general that ENTYVIO is indicated for ulcerative colitis and Crohn’s disease in adults (FDA indication excerpt provided), but the 2014 approval-year detail is not present in the supplied label excerpts.
Vedolizumab (Entyvio) is FDA-approved for ulcerative colitis.
Label indicates ENTYVIO is indicated in adults for moderately to severely active ulcerative colitis.
Vedolizumab (Entyvio) is FDA-approved for Crohn’s disease.
Label indicates ENTYVIO is indicated in adults for moderately to severely active Crohn’s disease.
Entyvio is an approved therapy for adults with ulcerative colitis.
Label indicates indication in adults for moderately to severely active ulcerative colitis.
Entyvio is an approved therapy for adults with Crohn’s disease.
Label indicates indication in adults for moderately to severely active Crohn’s disease.

Unsupported Statements

Vedolizumab (Entyvio) received FDA approval in 2014.
The provided FDA label excerpts do not include an approval-year statement.
Vedolizumab (Entyvio) was FDA-approved in 2014 for inflammatory bowel disease.
The provided FDA label excerpts include no approval-year information.
Entyvio is approved for adults with ulcerative colitis in cases where patients do not respond well to other treatments.
The provided label excerpt for Indications and Usage does not include a requirement that patients fail to respond to other treatments.
Entyvio is approved for adults with Crohn’s disease in cases where patients do not respond well to other treatments.
The provided label excerpt for Indications and Usage does not include a requirement that patients fail to respond to other treatments.

Contradictions

Important Omissions

No statement includes the label-specified disease activity requirement wording: “moderately to severely active” UC/CD.
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The only safety-relevant content (contraindications, warnings, infections/TB, hypersensitivity, interactions) is not addressed by the provided claims; the main issues are indication phrasing/approval-year support, not direct safety instruction.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Partially Aligned

Primary Issue
Two approval-year claims and two “not responding well to other treatments” claims are not supported by the provided FDA label excerpts.

Suggested Improvement
Limit indication statements to the label language provided (adults with moderately to severely active UC and CD) and remove the unsupported approval-year and “failed other treatments” requirement unless supported by the full label sections not included in the prompt.

Drug Brand Mention Assessment

Branding Score
47
Visibility
48
Mentioned
Ranking
#1
Sentiment
60
Recommendation Status
mentioned only
Brand Perception
Best Known For

Entyvio (vedolizumab) received FDA approval in 2014 for inflammatory bowel disease

Core Claims
  • Entyvio (vedolizumab) received FDA approval in 2014 for inflammatory bowel disease.
  • Entyvio is an approved therapy for adults with ulcerative colitis.
  • Entyvio is an approved therapy for adults with Crohn’s disease.
  • Even when FDA-approved, insurers may require prior authorization.
Differentiators
  • Specifies FDA approval in 2014 for inflammatory bowel disease.
  • Covers multiple indications: ulcerative colitis and Crohn’s disease.
  • Notes insurer prior-authorization documentation requirements.
Pricing Perception: Not Mentioned